Clinical trials: Anti-CD20 Therapy
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
- Trial name
- NCT00346684
- Testing
- Rituximab
- Where
- Germany
- Sponsor
- University of Cologne
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Pemphigus, Pemphigus Vulgaris (PV)
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
A prospective cohort study was conducted, following patients for 36 weeks from January 1, 2023, to April 30, 2024. Patients meeting the diagnostic criteria were nonrandomly grouped based on screening results.
- Trial name
- NCT06654817
- Testing
- Ofatumumab subcutaneous injection
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Chao Ji
Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma.
- Trial name
- NCT00003595
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma
DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- NCT04792489
- Testing
- zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine
- Where
- 32 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- Miltenyi Biomedicine GmbH
Early and Severe Systemic Sclerosis
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.
- Trial name
- NCT00379431
- Testing
- Administration of rituximab and methylprednisolone
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- University Hospital, Ghent
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20…
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06526000
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Novartis
Mantle Cell Lymphoma (MCL)
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naïve mantle cell lymphoma (MCL).
- Trial name
- NCT07855016
- Testing
- TT-01488 Tablets, Rituximab, Immunomodulatory Agent
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Multiple Sclerosis
WOE of Anti-CD20 Therapies
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single…
- Trial name
- NCT06121349
- Testing
- ocrelizumab, ofatumumab
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL.
- Trial name
- ELM-1 (NCT02290951)
- Testing
- Odronextamab multiple dose levels
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 200 people
- Sponsor
- Regeneron Pharmaceuticals
Anti-CD20 Monoclonal Antibody, BTK Inhibitors
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
This study aims to utilize anti-CD20 monoclonal antibodies to eliminate peripheral B cells and reduce the mechanism of autoantibody production, as well as combine the mechanism of BTK inhibitors (BTKi) blocking the B cell…
- Conditions
- Anti-CD20 Monoclonal Antibody, BTK Inhibitors, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07574073
- Testing
- Anti-CD20 monoclonal antibody and the BTK inhibitor
- Volunteers
- 30 people
- Sponsor
- Qi deng
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL)
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T…
- Conditions
- Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma
- Trial name
- NCT04186520
- Testing
- 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Medical College of Wisconsin
Lymphoma
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00012051
- Testing
- filgrastim, rituximab, carmustine
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 340 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Systemic Sclerosis (SSc), Systemic Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
This Phase 1b, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in…
- Conditions
- Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
- Trial name
- NCT07854483
- Testing
- C-CAR168
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
DALY II Japan/MB-CART2019.1 for DLBCL
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell…
- Trial name
- DALY II Japan (NCT07288879)
- Testing
- MB-CART2019.1
- Where
- 5 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Miltenyi Biomedicine GmbH
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20).
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Trial name
- EPCORE™ CLL-1 (NCT04623541)
- Testing
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 194 people
- Sponsor
- Genmab
Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy followed by rituximab or observation in treating patients who have stage III or stage IV low-grade non-Hodgkin's lymphoma.
- Conditions
- Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00003204
- Testing
- cyclophosphamide, fludarabine phosphate, vincristine sulfate
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal…
- Trial name
- NCT00556699
- Testing
- rituximab, SGN-40
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.